NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Kura Oncology, Inc. KURA
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$67.5M
▲ 25.2% vs FY2024
EPS · FY25
$-3.18
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-94.8%
Net margin · FY25
-412.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 67.5M
Revenue, FY2025 · full 19-year series below
Revenue
Net income
The company lost 413 cents on every revenue dollar this year.
Per share
USD -3.18
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-94.8%
Return on equity, FY2025
ROE
Operating margin-449.9%
Net margin-412.9%
Return on assets-37.2%
Each USD of equity lost 95 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.09B
Shares outstanding, FY2025
Change, 5 years+32.7%
Change, 10 years—
The share count grew 33% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 738.4M
total assets, end of FY2025
Total assetsUSD 738.4M
EquityUSD 174.1M
CashUSD 149.1M
Gross debtUSD 9.7M
Net debtUSD -139.4M
Current ratio6.06×
The company holds more cash than debt.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
0.1
0.1
0.0
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Operating income $B
−0.3
−0.2
−0.2
−0.1
·
·
·
·
·
·
·
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
EBITDA $B
−0.3
−0.2
−0.2
−0.1
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
·
·
Net income $B
−0.3
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−3.18
−2.02
−2.08
−2.03
−1.97
−1.69
−1.51
−1.72
−1.52
−1.47
−2.28
−0.01
−0.01
−0.01
−0.01
0.00
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−94.8
−42.9
−37.3
−29.3
−23.3
−21.6
−33.3
−50.2
−51.8
−39.7
−57.5
·
·
·
·
·
·
−184.6
−42.8
Shares out B
0.09
0.08
0.07
0.07
0.07
0.07
0.05
0.04
0.03
0.02
0.02
0.00
0.01
0.01
0.01
0.01
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
41 of 41
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed